Replies to post #374363 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

We’ve not been kept in the dark on the topic of Optune and it’s use in this trial. 6 patients went on to try it. You probably didn’t realize that the tumor treating fields was referring to the Optune device. Or you haven’t read the interim journal article. If not, I’d recommend familiarizing yourself with its content.

Since other treatments were allowed following disease progression, we assessed their usage in this trial. While on study, three patients (1%) had another resection, 103 patients (31%) received bevacizumab, 53 patients (16%) received CCNU and 6 patients (1.8%) were treated with tumor treating fields. In multiple reported studies, neither bevacizumab nor CCNU have been shown to extend survival [9, 25].
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6